Jasper Therapeutics, Inc. announced that the first patient has been dosed in Jasper's phase 1b/2a clinical study of subcutaneous briquilimab for the treatment of CSU called BEACON (a phase 1b/2a Briquilimab dose Escalation trial assessing ACtivity, safety, and pharmacOkinetics iN adult patients with chronic spontaneous urticaria). The BEACON study is evaluating repeat doses of subcutaneous Briquilimab in adult CSU patients who remain symptomatic after treatment with, or who cannot tolerate, omalizumab. Briquilimab (formerly JSP191) is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor.

Jasper is evaluating briquilimab as a treatment in patients with Chronic Spontaneous Urticaria, and will begin clinical development in Chronic Inducible Urticaria as well.